Sfoglia per Autore
Impact of intercurrent introduction of steroids on clinical outcomes in advanced non-small-cell lung cancer (Nsclc) patients under immune-checkpoint inhibitors (ici)
2020 De Giglio A.; Mezquita L.; Auclin E.; Blanc-Durand F.; Riudavets M.; Caramella C.; Martinez G.; Benitez J.C.; Martin-Romano P.; El-Amarti L.; Hendriks L.; Ferrara R.; Naltet C.; Lavaud P.; Gazzah A.; Adam J.; Planchard D.; Chaput N.; Besse B.
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer
2020 Ricciuti B.; Brambilla M.; Cortellini A.; De Giglio A.; Ficorella C.; Sidoni A.; Bellezza G.; Crino L.; Ludovini V.; Baglivo S.; Metro G.; Chiari R.
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort (Cancer Immunology, Immunotherapy, (2020), 69, 7, (1177-1187), 10.1007/s00262-020-02536-5)
2020 Naqash A.R.; Ricciuti B.; Owen D.H.; Florou V.; Toi Y.; Cherry C.; Hafiz M.; De Giglio A.; Muzaffar M.; Patel S.H.; Sugawara S.; Burkart J.; Park W.; Chiari R.; Sugisaka J.; Otterson G.A.; de Lima Lopes G.; Walker P.R.
Clinical consideration for choosing combination therapies in advanced non-small-cell lung cancer: Age, Eastern Cooperative Organization performance status 2, steroids and antibiotics
2020 de Giglio A.; Nuvola G.; Baldini C.
PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis
2021 Di Federico A.; De Giglio A.; Nuvola G.; Deiana C.; Conci N.; Gelsomino F.; Ardizzoni A.
Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis
2021 Di Federico A.; De Giglio A.; Parisi C.; Gelsomino F.; Boni L.; Ardizzoni A.
An overview on molecular characterization of thymic tumors: Old and new targets for clinical advances
2021 Tateo V.; Manuzzi L.; Parisi C.; De Giglio A.; Campana D.; Pantaleo M.A.; Lamberti G.
Prognostic relevance of pleural invasion for resected NSCLC patients undergoing adjuvant treatments: A propensity score-matched analysis of SEER database
2021 De Giglio A.; Di Federico A.; Gelsomino F.; Ardizzoni A.
Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: A challenging case enhances the need for a multidisciplinary approach
2021 De Giglio A.; Scorsetti M.; Franceschini D.; Massari F.; Ardizzoni A.
PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy
2021 Di Federico A.; De Giglio A.; Parisi C.; Gelsomino F.; Ardizzoni A.
Antibody–drug conjugates for lung cancer in the era of personalized oncology
2021 Ricciuti B.; Lamberti G.; Andrini E.; Genova C.; De Giglio A.; Bianconi V.; Sahebkar A.; Chiari R.; Pirro M.
STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
2021 Di Federico A.; De Giglio A.; Parisi C.; Gelsomino F.
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study
2021 Cortellini A.; De Giglio A.; Cannita K.; Cortinovis D.L.; Cornelissen R.; Baldessari C.; Giusti R.; D'Argento E.; Grossi F.; Santoni M.; Catino A.; Berardi R.; Sforza V.; Rossi G.; Antonuzzo L.; Di Noia V.; Signorelli D.; Gelibter A.; Occhipinti M.A.; Follador A.; Rastelli F.; Chiari R.; Gravara L.D.; Inno A.; De Tursi M.; Di Marino P.; Mansueto G.; Zoratto F.; Filetti M.; Montrone M.; Citarella F.; Pensieri M.V.; Russano M.; Cantini L.; Nigro O.; Leonetti A.; Bordi P.; Minuti G.; Landi L.; De Toma A.; Donisi C.; Ricciardi S.; Migliorino M.R.; Napoli V.M.; Leone G.; Metro G.; Banna G.L.; Friedlaender A.; Addeo A.; Ficorella C.; Porzio G.
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors
2021 Dall'Olio F.G.; Gelsomino F.; Conci N.; Marcolin L.; De Giglio A.; Grilli G.; Sperandi F.; Fontana F.; Terracciano M.; Fragomeno B.; Tober N.; Manferrari G.; Brocchi S.; Golfieri R.; Fiorentino M.; Ardizzoni A.
IMpower 132: Is the Second Exception to the Rule No Longer an Exception?
2021 Di Federico A.; Nuvola G.; Deiana C.; Donati G.; De Giglio A.
Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078] (ESMO Open (2021) 6(2), (S205970292100034X), (10.1016/j.esmoop.2021.100078))
2021 Banna G.L.; Cortellini A.; Cortinovis D.L.; Tiseo M.; Aerts J.G.J.V.; Barbieri F.; Giusti R.; Bria E.; Grossi F.; Pizzutilo P.; Berardi R.; Morabito A.; Genova C.; Mazzoni F.; Di Noia V.; Signorelli D.; Gelibter A.; Macerelli M.; Rastelli F.; Chiari R.; Rocco D.; Gori S.; De Tursi M.; Di Marino P.; Mansueto G.; Zoratto F.; Filetti M.; Montrone M.; Citarella F.; Marco R.; Cantini L.; Nigro O.; D'Argento E.; Buti S.; Minuti G.; Landi L.; Guaitoli G.; Lo Russo G.; De Toma A.; Donisi C.; Friedlaender A.; De Giglio A.; Metro G.; Porzio G.; Ficorella C.; Addeo A.
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
2021 Banna G.L.; Cortellini A.; Cortinovis D.L.; Tiseo M.; Aerts J.G.J.V.; Barbieri F.; Giusti R.; Bria E.; Grossi F.; Pizzutilo P.; Berardi R.; Morabito A.; Genova C.; Mazzoni F.; Di Noia V.; Signorelli D.; Gelibter A.; Macerelli M.; Rastelli F.; Chiari R.; Rocco D.; Gori S.; De Tursi M.; Di Marino P.; Mansueto G.; Zoratto F.; Filetti M.; Montrone M.; Citarella F.; Marco R.; Cantini L.; Nigro O.; D'Argento E.; Buti S.; Minuti G.; Landi L.; Guaitoli G.; Lo Russo G.; De Toma A.; Donisi C.; Friedlaender A.; De Giglio A.; Metro G.; Porzio G.; Ficorella C.; Addeo A.
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
2021 De Giglio A.; Di Federico A.; Nuvola G.; Deiana C.; Gelsomino F.
Advanced non-small-cell lung cancer: how to manage non-oncogene disease
2022 De Giglio A.; Di Federico A.; Deiana C.; Ricciuti B.; Brambilla M.; Metro G.
Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer
2022 De Giglio A.; Di Federico A.; Metro G.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Impact of intercurrent introduction of steroids on clinical outcomes in advanced non-small-cell lung cancer (Nsclc) patients under immune-checkpoint inhibitors (ici) | De Giglio A.; Mezquita L.; Auclin E.; Blanc-Durand F.; Riudavets M.; Caramella C.; Martinez G.; B...enitez J.C.; Martin-Romano P.; El-Amarti L.; Hendriks L.; Ferrara R.; Naltet C.; Lavaud P.; Gazzah A.; Adam J.; Planchard D.; Chaput N.; Besse B. | 2020-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-12-02827.pdf; cancers-12-02827-s001.pdf |
| Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer | Ricciuti B.; Brambilla M.; Cortellini A.; De Giglio A.; Ficorella C.; Sidoni A.; Bellezza G.; Cri...no L.; Ludovini V.; Baglivo S.; Metro G.; Chiari R. | 2020-01-01 | CLINICAL & TRANSLATIONAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort (Cancer Immunology, Immunotherapy, (2020), 69, 7, (1177-1187), 10.1007/s00262-020-02536-5) | Naqash A.R.; Ricciuti B.; Owen D.H.; Florou V.; Toi Y.; Cherry C.; Hafiz M.; De Giglio A.; Muzaff...ar M.; Patel S.H.; Sugawara S.; Burkart J.; Park W.; Chiari R.; Sugisaka J.; Otterson G.A.; de Lima Lopes G.; Walker P.R. | 2020-01-01 | CANCER IMMUNOLOGY, IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| Clinical consideration for choosing combination therapies in advanced non-small-cell lung cancer: Age, Eastern Cooperative Organization performance status 2, steroids and antibiotics | de Giglio A.; Nuvola G.; Baldini C. | 2020-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis | Di Federico A.; De Giglio A.; Nuvola G.; Deiana C.; Conci N.; Gelsomino F.; Ardizzoni A. | 2021-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis | Di Federico A.; De Giglio A.; Parisi C.; Gelsomino F.; Boni L.; Ardizzoni A. | 2021-01-01 | JTO CLINICAL AND RESEARCH REPORTS | - | 1.01 Articolo in rivista | PIIS2666364321000734.pdf |
| An overview on molecular characterization of thymic tumors: Old and new targets for clinical advances | Tateo V.; Manuzzi L.; Parisi C.; De Giglio A.; Campana D.; Pantaleo M.A.; Lamberti G. | 2021-01-01 | PHARMACEUTICALS | - | 1.01 Articolo in rivista | pharmaceuticals-14-00316.pdf |
| Prognostic relevance of pleural invasion for resected NSCLC patients undergoing adjuvant treatments: A propensity score-matched analysis of SEER database | De Giglio A.; Di Federico A.; Gelsomino F.; Ardizzoni A. | 2021-01-01 | LUNG CANCER | - | 1.01 Articolo in rivista | - |
| Bilateral radiation recall pneumonitis during immunotherapy for an advanced renal cell carcinoma: A challenging case enhances the need for a multidisciplinary approach | De Giglio A.; Scorsetti M.; Franceschini D.; Massari F.; Ardizzoni A. | 2021-01-01 | EUROPEAN JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
| PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy | Di Federico A.; De Giglio A.; Parisi C.; Gelsomino F.; Ardizzoni A. | 2021-01-01 | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Antibody–drug conjugates for lung cancer in the era of personalized oncology | Ricciuti B.; Lamberti G.; Andrini E.; Genova C.; De Giglio A.; Bianconi V.; Sahebkar A.; Chiari R....; Pirro M. | 2021-01-01 | SEMINARS IN CANCER BIOLOGY | - | 1.01 Articolo in rivista | - |
| STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive? | Di Federico A.; De Giglio A.; Parisi C.; Gelsomino F. | 2021-01-01 | EUROPEAN JOURNAL OF CANCER | - | 1.01 Articolo in rivista | - |
| Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study | Cortellini A.; De Giglio A.; Cannita K.; Cortinovis D.L.; Cornelissen R.; Baldessari C.; Giusti R....; D'Argento E.; Grossi F.; Santoni M.; Catino A.; Berardi R.; Sforza V.; Rossi G.; Antonuzzo L.; Di Noia V.; Signorelli D.; Gelibter A.; Occhipinti M.A.; Follador A.; Rastelli F.; Chiari R.; Gravara L.D.; Inno A.; De Tursi M.; Di Marino P.; Mansueto G.; Zoratto F.; Filetti M.; Montrone M.; Citarella F.; Pensieri M.V.; Russano M.; Cantini L.; Nigro O.; Leonetti A.; Bordi P.; Minuti G.; Landi L.; De Toma A.; Donisi C.; Ricciardi S.; Migliorino M.R.; Napoli V.M.; Leone G.; Metro G.; Banna G.L.; Friedlaender A.; Addeo A.; Ficorella C.; Porzio G. | 2021-01-01 | THORACIC CANCER | - | 1.01 Articolo in rivista | Thoracic Cancer - 2021 - Cortellini - Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients A.pdf |
| PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors | Dall'Olio F.G.; Gelsomino F.; Conci N.; Marcolin L.; De Giglio A.; Grilli G.; Sperandi F.; Fontan...a F.; Terracciano M.; Fragomeno B.; Tober N.; Manferrari G.; Brocchi S.; Golfieri R.; Fiorentino M.; Ardizzoni A. | 2021-01-01 | CLINICAL LUNG CANCER | - | 1.01 Articolo in rivista | - |
| IMpower 132: Is the Second Exception to the Rule No Longer an Exception? | Di Federico A.; Nuvola G.; Deiana C.; Donati G.; De Giglio A. | 2021-01-01 | JOURNAL OF THORACIC ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078] (ESMO Open (2021) 6(2), (S205970292100034X), (10.1016/j.esmoop.2021.100078)) | Banna G.L.; Cortellini A.; Cortinovis D.L.; Tiseo M.; Aerts J.G.J.V.; Barbieri F.; Giusti R.; Bri...a E.; Grossi F.; Pizzutilo P.; Berardi R.; Morabito A.; Genova C.; Mazzoni F.; Di Noia V.; Signorelli D.; Gelibter A.; Macerelli M.; Rastelli F.; Chiari R.; Rocco D.; Gori S.; De Tursi M.; Di Marino P.; Mansueto G.; Zoratto F.; Filetti M.; Montrone M.; Citarella F.; Marco R.; Cantini L.; Nigro O.; D'Argento E.; Buti S.; Minuti G.; Landi L.; Guaitoli G.; Lo Russo G.; De Toma A.; Donisi C.; Friedlaender A.; De Giglio A.; Metro G.; Porzio G.; Ficorella C.; Addeo A. | 2021-01-01 | ESMO OPEN | - | 1.01 Articolo in rivista | PIIS205970292100096X.pdf |
| The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer | Banna G.L.; Cortellini A.; Cortinovis D.L.; Tiseo M.; Aerts J.G.J.V.; Barbieri F.; Giusti R.; Bri...a E.; Grossi F.; Pizzutilo P.; Berardi R.; Morabito A.; Genova C.; Mazzoni F.; Di Noia V.; Signorelli D.; Gelibter A.; Macerelli M.; Rastelli F.; Chiari R.; Rocco D.; Gori S.; De Tursi M.; Di Marino P.; Mansueto G.; Zoratto F.; Filetti M.; Montrone M.; Citarella F.; Marco R.; Cantini L.; Nigro O.; D'Argento E.; Buti S.; Minuti G.; Landi L.; Guaitoli G.; Lo Russo G.; De Toma A.; Donisi C.; Friedlaender A.; De Giglio A.; Metro G.; Porzio G.; Ficorella C.; Addeo A. | 2021-01-01 | ESMO OPEN | - | 1.01 Articolo in rivista | 1-s2.0-S205970292100034X-main.pdf; ScienceDirect_files_31Aug2023_10-43-00.826.zip |
| The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines) | De Giglio A.; Di Federico A.; Nuvola G.; Deiana C.; Gelsomino F. | 2021-01-01 | CURRENT ONCOLOGY REPORTS | - | 1.01 Articolo in rivista | - |
| Advanced non-small-cell lung cancer: how to manage non-oncogene disease | De Giglio A.; Di Federico A.; Deiana C.; Ricciuti B.; Brambilla M.; Metro G. | 2022-01-01 | DRUGS IN CONTEXT | - | 1.01 Articolo in rivista | dic.2022-2-4.pdf |
| Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer | De Giglio A.; Di Federico A.; Metro G. | 2022-01-01 | TRANSLATIONAL LUNG CANCER RESEARCH | - | 1.01 Articolo in rivista | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile